Value-Based Cardiology


Cardiologists were thrilled with results of the FOURIER trial, but payers were less moved. Given the drug's $14,000 a year price, some wanted to know if they would see more than the 30% to 35% discounts they had been offered.
The alliance based at Johns Hopkins seeks to promote high-value healthcare and educate the next generation of medical students in these principles.
John B. Buse, MD, PhD, discusses the efficacy and safety findings from the EMPA-REG OUTCOME trial with empagliflozin in patients with type 2 diabetes mellitus.
The review reports that fewer than 50% of patients with diabetes are being treated according guidelines to prevent a cardiovascular event.
Louis S. Christos, RPh, provides insight regarding the recent cardiovascular outcomes data with antidiabetes medications.


July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST